Stock Worth Watching: Alkermes PLC Stock Increased as Institutional Investors Enter

December 1, 2016 - By Clifton Ray   ·   0 Comments

Stock Worth Watching: Alkermes PLC Stock Increased as Institutional Investors Enter

Sentiment for Alkermes PLC (NASDAQ:ALKS)

Alkermes PLC (NASDAQ:ALKS) institutional sentiment increased to 1.2 in Q2 2016. Its up 0.24, from 0.96 in 2016Q1. The ratio increased, as 102 hedge funds opened new or increased stock positions, while 106 reduced and sold positions in Alkermes PLC. The hedge funds in our partner’s database now possess: 135.77 million shares, down from 136.92 million shares in 2016Q1. Also, the number of hedge funds holding Alkermes PLC in their top 10 stock positions decreased from 4 to 2 for a decrease of 2. Sold All: 31 Reduced: 75 Increased: 68 New Position: 34.

Alkermes Public Limited Company is a biopharmaceutical company. The company has a market cap of $8.23 billion. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

About 628,038 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 37.64% since April 28, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Analysts await Alkermes Plc (NASDAQ:ALKS) to report earnings on February, 23. They expect $-0.19 earnings per share, up 36.67% or $0.11 from last year’s $-0.3 per share. After $-0.25 actual earnings per share reported by Alkermes Plc for the previous quarter, Wall Street now forecasts -24.00% EPS growth.

According to Zacks Investment Research, “Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes’ pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.”

Meditor Group Ltd holds 18.13% of its portfolio in Alkermes Plc for 1.03 million shares. Opus Point Partners Management Llc owns 82,858 shares or 3.46% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 2.1% invested in the company for 104,962 shares. The Massachusetts-based Camber Capital Management Llc has invested 1.96% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 40,000 shares.#img1#

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Ratings analysis reveals 75% of Alkermes’s analysts are positive. Out of 8 Wall Street analysts rating Alkermes, 6 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $35 while the high is $85. The stock’s average target of $58.86 is 6.36% above today’s ($55.34) share price. ALKS was included in 16 notes of analysts from September 1, 2015. The firm has “Buy” rating given on Friday, July 29 by Jefferies. The firm has “Overweight” rating by Barclays Capital given on Friday, July 29. The rating was downgraded by JP Morgan to “Neutral” on Thursday, January 21. Leerink Swann maintained the shares of ALKS in a report on Thursday, January 21 with “Outperform” rating. The firm has “Market Perform” rating given on Tuesday, July 26 by Cowen & Co. Cowen & Co downgraded the stock to “Market Perform” rating in Thursday, January 21 report. The rating was maintained by UBS on Friday, January 22 with “Neutral”. Barclays Capital maintained Alkermes Plc (NASDAQ:ALKS) on Wednesday, July 13 with “Overweight” rating. On Tuesday, September 1 the stock rating was upgraded by Morgan Stanley to “Overweight”. On Wednesday, October 7 the stock rating was maintained by Barclays Capital with “Overweight”.

ALKS Company Profile

Alkermes Public Limited Company, incorporated on May 4, 2011, is a biopharmaceutical company. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. The Company’s products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. The Company’s product platforms include injectable extended release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

More recent Alkermes Plc (NASDAQ:ALKS) news were published by: Fool.com which released: “Why Alkermes PLC Skyrocketed Today” on October 21, 2016. Also Fool.com published the news titled: “Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward” on November 07, 2016. Businesswire.com‘s news article titled: “Alkermes plc Reports Third Quarter 2016 Financial Results” with publication date: November 02, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>